NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Mologen AG (XETRA: MGNK)

 
MGNK Technical Analysis
5
As on 16th Dec 2021 MGNK STOCK Price closed @ 0.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.04 & Strong Sell for SHORT-TERM with Stoploss of 0.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MGNKSTOCK Price

Open 0.02 Change Price %
High 0.02 1 Day -0.01 -50.00
Low 0.01 1 Week 0.00 0.00
Close 0.01 1 Month -0.01 -50.00
Volume 1932 1 Year -0.08 -88.89
52 Week High 0.09 | 52 Week Low 0.01
 
XETRA Germany Most Active Stocks
LHAR 2.05 -20.23%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BVBA 0.02 -60.00%
SNH 0.16 6.67%
SNH 0.16 6.67%
SNH 0.16 6.67%
AT1 2.14 %
AT1 2.14 %
 
XETRA Germany Top Gainers Stocks
ASKN 0.73 73.81%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
 
XETRA Germany Top Losers Stocks
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
BVBA 0.02 -60.00%
SD1 0.13 -51.85%
MGNK 0.01 -50.00%
MGNK 0.01 -50.00%
MGNK 0.01 -50.00%
CNW 0.24 -29.41%
 
 
MGNK
Daily Charts
MGNK
Intraday Charts
Whats New @
Bazaartrend
MGNK
Free Analysis
 
MGNK Important Levels Intraday
RESISTANCE0.03
RESISTANCE0.02
RESISTANCE0.02
RESISTANCE0.02
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT-0.01
 
MGNK Forecast July 2024
4th UP Forecast0.09
3rd UP Forecast0.06
2nd UP Forecast0.05
1st UP Forecast0.03
1st DOWN Forecast-0.01
2nd DOWN Forecast-0.03
3rd DOWN Forecast-0.04
4th DOWN Forecast-0.07
 
MGNK Weekly Forecast
4th UP Forecast0.03
3rd UP Forecast0.02
2nd UP Forecast0.02
1st UP Forecast0.02
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast-0.01
 
MGNK Forecast2024
4th UP Forecast0.18
3rd UP Forecast0.13
2nd UP Forecast0.09
1st UP Forecast0.06
1st DOWN Forecast-0.04
2nd DOWN Forecast-0.07
3rd DOWN Forecast-0.11
4th DOWN Forecast-0.16
 
Mologen AG ( XETRA Germany Symbol : MGNK )
Sector : N/A And Other Stocks in Same Sector
 
MGNK Other Details
Segment EQ
Market Capital 955061.00
Sector
Industry
Offical website >
 
MGNK Address
MGNK
 
MGNK Latest News
 
Your Comments and Response on Mologen AG
 
MGNK Business Profile
Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and human immunodeficiency virus (HIV). The company's lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase III study for the treatment of metastatic colorectal cancer; Phase II trial for the treatment of small-cell lung cancer; and Phase Ib/IIa study of lefitolimod in HIV infected patients under antiretroviral therapy through collaborations with the Aarhus University Hospital in Denmark. Its lead product Lefitolimod is also under Phase I combination study with the checkpoint inhibitor Yervoy to treat advanced solid tumors in collaboration with MD Anderson Cancer Center at the University of Texas, the United States. In addition, the company is involved in the development of EnanDIM molecules, which are under pre-clinical development for cancer/anti-infective therapies; and MGN1601, a cell based therapeutic vaccine, which has completed Phase I/II trial for the treatment of renal cancer. Mologen AG was founded in 1998 and is headquartered in Berlin, Germany. Address: Fabeckstrasse 30, Berlin, Germany, 14195
 
2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service